Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. J Rheumatol, 49, 1221-1228.īraun J, Kiltz U, Deodhar A, Tomita T, Dougados M, Bolce R, Sandoval D, Lin CY, Walsh J (2021). Impact of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey. Gossec L, Walsh JA, Michaud K, Holdsworth E, Peterson S, Meakin S, Yang F, Booth N, Chakravarty SD, Piercy J, Dennis N, Ogdie A (2022). Women with Psoriatic Arthritis Experience Higher Disease Burden than Men: Findings from a Real-World Survey in the USA and Europe. Gossec L, Walsh JA, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Chakravarty SD, Ogdie A (2022). Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as biomarkers in axial spondyloarthritis: observational studies from the PULSAR registry. Sen R, Kim E, Napier RJ, Cheng E, Fernandez A, Manning ES, Anderson ER, Maier KD, Hashim M, Kerr GS, Fang MA, Hou JK, Chang E, Walsh JA, Raychadhuri SP, Reimold A, Caplan L (2022). Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States. Pizzicato LN, Vadhariya A, Birt J, Ketkar AG, Bolce R, Grabner M, Pepe RS, Walsh JA (2022). ![]() Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe. Walsh JA, Ogdie A, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Dalby CM, Chakravarty SD, Dennis N, Gossec L (2023).Responsiveness and minimal clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis. ![]() Karmacharya P, Stull C, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Ogdie A, Walsh JA (2023). Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies. ACR Open Rheumatol, 5(5), 264-276.īaraliakos X, Ranza R, str A, Ciccia F, Coates LC, Rednic S, Walsh JA, Douglas K, Gao T, Kato K, Song IH, Ganz F, Deodhar A (2023). The International Map of Axial Spondyloarthritis Survey: A US Patient Perspective on Diagnosis and Burden of Disease. Magrey M, Walsh JA, Flierl S, Howard RA, Calheiros RC, Wei D, Khan MA (2023). Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2. Kiltz U, Kishimoto M, Walsh JA, Sampaio-Barros P, Mittal M, Saffore CD, Wung P, Ganz F, Biljan A, Poddubnyy D (2023).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |